清肺散结丸辅助经皮穿刺氩氦刀靶向冷冻治疗老年晚期非小细胞肺癌临床研究

魏亚强1，张晓飞 1，汪海燕 2

1.延安市人民医院，陕西 延安 716000；2.甘肃中医药大学附属医院，甘肃 兰州 730000摘要：目的 观察清肺散结丸辅助经皮穿刺氩氦刀靶向冷冻治疗老年晚期非小细胞肺癌（NSCLC）的疗效及其对免疫功能的影响。方法 采用抽签法将 94 例老年晚期 NSCLC患者分为观察组与对照组各 47 例。

2 组均采用经皮穿刺氩氦刀靶向冷冻治疗，手术后复查 CT，观察病灶情况。观察组并予清肺散结丸，每次 1瓶，每日2次，口服，共治疗3个月。评价2组近期疗效，观察2组治疗前后 IgG、IgA、CD3+、CD4+、CD8+水平及术后并发症。观察2 组 1、2、3年生存率。结果 观察组和对照组分别脱落2、3例。观察组总有效率为 84.4%（38/45），对照组为 65.9%（29/44），2组比较差异有统计学意义（P＜0.05）。与本组治疗前比较，2组治疗后 IgG、IgA、CD3+、CD4+、CD8+水平明显升高（P＜0.05），治疗组治疗后 IgG、IgA、CD3+、CD4+、

CD8+水平高于对照组（P＜0.05）。治疗后，观察组咳嗽加重、术后疼痛、痰中带血、发热及恶心呕吐的发生

率均低于对照组（P＜0.05）。观察组 1、2、3年生存率分别为 91.1%、75.6%、64.4%，对照组分别为 79.5%、

63.6%、52.3%，2 组相同时点比较差异有统计学意义（P＜0.05）。结论 清肺散结丸辅助经皮穿刺氩氦刀靶向冷冻治疗老年晚期NSCLC疗效较好，可改善患者免疫功能，提高生存率。关键词：清肺散结丸；氩氦刀靶向冷冻治疗；老年；晚期；非小细胞肺癌

DOI：10.3969/j.issn.1005-5304.2017.11.007

中图分类号：R273.42 文献标识码：A 文章编号：1005-5304(2017)11-0026-04

Clinical Study on Qingfei Sanjie Pills Combined with Targeted Cryoablation Therapy for Treatment of Elderly Patients with Advanced Non-Small Cell Lung Cancer

WEI Ya-qiang1, ZHANG Xiao-fei1, WANG Hai-yan2 (1. People’s Hospital of Yan’an, Yan’an 716000, China; 2. Affiliated Hospital of Gansu University of Chinese Medicine, Lanzhou 730000, China)

Abstract: Objective To study the clinical efficacy of Qingfei Sanjie Pills combined with targeted cryoablation therapy on elderly patients with advanced non-small cell lung cancer (NSCLC) and its influence on the levels of immune function in patients. Methods Totally 94 elderly patients with NSCLC were divided into observation group and control group, with 47 cases in each group. Both groups were given targeted cryoablation therapy and under CT review after surgery to observe lesions condition. Observation group was given Qingfei Sanjie Pills, once a bottle, twice a day, orally, for three months. Recent efficacy of the two groups were evaluated. The levels of IgG, IgA, CD3+, CD4+, CD8+, and complications in the two groups were detected. The survival rate of 1 year, 2 years and 3 years in the two groups were observed. Results Two cases in the observation group and three cases in the control group were invalid. The total effective rate was 84.4% (38/45) in observation group and 65.9% (29/44) in the control group, with statistical significance (P<0.05). After the treatment, the levels of IgG, IgA, CD3+, CD4+ and CD8+ in the observation group were significantly higher than the control group (P<0.05). After treatment, the incidence rates of increased cough, postoperative pain, bloody sputum, fever and nausea and vomiting in the observation group were lower than the control group. The 1 year, 2 years and 3 years survival rates were 91.1%, 75.6% and 64.4% in observation group, and 79.5%, 63.6% and 52.3% in the control group, with statistical significance (P<0.05). Conclusion Qingfei Sanjie Pills combined with targeted cryoablation therapy on elderly patients with advanced NSCLC has good clinical efficacy, which can improve immune system of patients and increase survival rate.

Key words: Qingfei Sanjie Pills; targeted cryoablation therapy; elderly; advanced; non small cell lung cancer 通讯作者：汪海燕，E-mail：wanghaiyan2001@163.com